Proteome-wide mendelian randomization study implicates therapeutic targets in common cancers

Table 1 MR analysis results and reverse causality detection for 16 plasma proteins significant related with cancers

Cancers	Proteins	SNP	Unipoint	OR (95%)	P	PVE (%)	Steiger filtering	Bidirectional MR P-value (IVW/MR-egger)	F
Prostate cancer	KDELC2	rs74911261	Q7Z4H8	0.89 (0.86, 0.93)	1.89E−08	8.61	8.23E−60	0.189^b	310.89
	SPINT2	rs71354995	A0A140VJV6	1.05 (1.03, 1.06)	1.49E−06	36.59	NA	0.231^b	1905.11
	TNFRSF10B	rs4871844	O14763	0.74 (0.65, 0.83)	2.41E−07	0.94	3.19E−06	0.228^b	30.25
	GSTP1	rs1695	P09211	0.82 (0.74, 0.90)	1.82E−05	1.47	3.14E−10	0.337^b	49.17
	IGF2R	rs629849	P11717	0.92 (0.90, 0.94)	4.57E−10	18.27	7.55E−138	0.026^b	738
	CTSS	rs41271951	P25774	0.91 (0.88, 0.95)	2.56E−07	11.33	2.24E−81	0.806^b	421.77
	HDGF	rs4399146	P51858	1.14 (1.07, 1.21)	5.73E−05	3.01	3.62E−20	0.015^b	99.26
Breast cancer	CPNE1	rs12481228	Q99829	0.96 (0.94, 0.98)	5.15E−05	16.76	1.24E−130	0.979^b	664.52
	PDIA3	rs3110081	P30101	1.19 (1.10, 1.30)	3.20E−05	1.14	3.39E−08	0.315^b	36.75
	GDI2	rs2890364	P50395	0.85 (0.80, 0.91)	3.34E−06	1.75	4.19E−12	0.598^b	57.03
	ISLR2	rs2959011	Q6UXK2	0.87 (0.82, 0.93)	4.27E−05	1.71	2.19E−12	0.336^b	57.55
	CTSF	rs1791679	Q9UBX1	1.14 (1.08, 1.21)	7.53E−06	2.26	5.40E−16	0.245^b	76.25
Lung cancer	SFTPB	rs1130866	P07988	0.93 (0.91, 0.95)	6.36E−09	46.61	3.77E−178	0.771^b	972.31
	CTSH	rs34593439	P09668	1.07 (1.05, 1.10)	1.71E−08	49.95	1.07E−199	0.002^a	1098.94
	ICAM5	rs281439	Q8N6I2	0.95 (0.93, 0.97)	2.94E−05	53.15	9.08E−219	0.217^b	1194.8
	FLRT3	rs11908097	Q9NZU0	1.10 (1.05, 1.15)	2.16E−05	14.37	2.90E−50	0.217^b	255.54

PVE: proportion of variance explained; IVW: inverse variance weighted; OR: Odds ratios; SNP: single nucleotide polymorphism; a: The P-value of MR-egger; b: The P-value of MR-IVW

ISSN: 1479-5876